A Phase 2, Multicenter, Randomized, Parallel-Arm, Placebo-Controlled Study of LY3074828 in Subjects with Active Crohn’s Disease

Purpose

To determine whether LY3074828 can help patients with Crohn’s disease.  In addition we hope to learn more information regarding the safety of LY3074828 and any side effects

Criteria

Stipend: $50.00 / visit

Subjects ≥18 and ≤75 years of age

Diagnosis of Crohn’s disease for ≥3 months

Experiencing active Crohn’s disease       

Have received prior treatment for Crohn’s disease

History of inadequate response to, or failure to tolerate treatment with aminosalicylates, 6-mercaptopurine (6-MP) or azathioprine (AZA), oral or IV corticosteroids or history of corticosteroid dependence (an inability to successfully taper corticosteroids without return of Crohn’s disease) OR Have received treatment with ≥1 biologic agents (such as TNF antagonists, vedolizumab, experimental biologic Crohn’s disease therapeutics) with or without documented history of failure to respond to or tolerate such treatment

Can not:       

Have a diagnosis of conditions affecting the digestive tract, such as UC, indeterminate colitis, fistulizing disease, abdominal or perianal abscess, adenomatous colonic polyps not excised, colonic mucosal dysplasia, and short bowel syndrome       

Have hepatitis B or have hepatitis C      

Diagnosis with Clostridium difficile (C diff) infection within 60 days of screening or test positive at screening, or other intestinal pathogen

Details

Contact Principal Investigator for Information

Interested in more information? Contact Us:

Sunny Hussain, M.D., Principal Investigator
(318) 212-8130

IRB: CGIRB
IRB Number:
Trial Type: Drug
Sponsor: Eli Lilly